Gasparić Maja, Rubio Ivonne, Thönes Nadja, Gissmann Lutz, Müller Martin
Deutsches Krebsforschungszentrum, Forschungsschwerpunkt Infektionen und Krebs, Im Neuenheimer Feld 242, 69120 Heidelberg, Germany.
Vaccine. 2007 Jun 6;25(23):4540-53. doi: 10.1016/j.vaccine.2007.04.001. Epub 2007 Apr 20.
At least 15 different papillomavirus types are causatively associated with the development of tumors in humans. Since the middle of 2006 a protective, virus-like particle based vaccine against the tumor-related HPV types 16 and 18 is commercially available. We investigated the possibility of applying DNA vaccination to obtain protective antibody responses against multiple papillomavirus types. Our data indicate that low amounts of DNA were sufficient to induce neutralizing antibodies in mice although a DNA dose-dependency in respect to the L1-specific antibody titers was observed. Furthermore, we found that immune responses against different PV types could be induced by simultaneous DNA vaccination with a mixture of expression vectors encoding L1 proteins of different papillomavirus types. However, we observed that there was a strong interference when plasmids encoding different L1 genes were used together. HPV 16 responses were repressed by co-administration of HPV 11 and/or BPV 1 L1 expression constructs. Likewise, BPV 1 responses were repressed by co-administration of HPV 16 or HPV 11 L1 plasmids. This interference could be overcome by administration of the different constructs into different sites of the animals or by sequential immunization. Thus, our results suggest that the mode of repression was due to interference with L1 particle assembly and was not a consequence of immunodominance of certain L1 proteins.
至少15种不同的乳头瘤病毒类型与人类肿瘤的发生有因果关系。自2006年年中以来,一种针对与肿瘤相关的人乳头瘤病毒16型和18型的基于病毒样颗粒的预防性疫苗已上市销售。我们研究了应用DNA疫苗获得针对多种乳头瘤病毒类型的保护性抗体反应的可能性。我们的数据表明,低剂量的DNA足以在小鼠中诱导中和抗体,尽管观察到L1特异性抗体滴度存在DNA剂量依赖性。此外,我们发现,通过同时用编码不同乳头瘤病毒类型L1蛋白的表达载体混合物进行DNA疫苗接种,可以诱导针对不同乳头瘤病毒类型的免疫反应。然而,我们观察到,当一起使用编码不同L1基因的质粒时,存在强烈的干扰。人乳头瘤病毒16型的反应会因同时施用11型人乳头瘤病毒和/或牛乳头瘤病毒1型L1表达构建体而受到抑制。同样,牛乳头瘤病毒1型的反应会因同时施用16型人乳头瘤病毒或11型人乳头瘤病毒L1质粒而受到抑制。这种干扰可以通过将不同的构建体注射到动物的不同部位或通过顺序免疫来克服。因此,我们的结果表明,抑制模式是由于对L1颗粒组装的干扰,而不是某些L1蛋白免疫显性的结果。